In vivo hippocampal subfield volumes in bipolar disorder—A mega-analysis from The Enhancing Neuro Imaging Genetics through Meta-Analysis Bipolar Disorder Working Group by Haukvik, U.K. et al.
R E S E A R CH A R T I C L E
In vivo hippocampal subfield volumes in bipolar disorder—A
mega-analysis from The Enhancing Neuro Imaging Genetics
through Meta-Analysis Bipolar Disorder Working Group
Unn K. Haukvik1,2 | Tiril P. Gurholt2,3,4 | Stener Nerland3,4 |
Torbjørn Elvsåshagen2,5,6 | Theophilus N. Akudjedu7,8 | Martin Alda9,10 |
Dag Alnæs3,2 | Silvia Alonso-Lana11 | Jochen Bauer12 | Bernhard T. Baune13,14,15 |
Francesco Benedetti16,17 | Michael Berk18,19 | Francesco Bettella2 |
Erlend Bøen20 | Caterina M. Bonnín21 | Paolo Brambilla22,23 |
Erick J. Canales-Rodríguez11 | Dara M. Cannon7 | Xavier Caseras24 |
Orwa Dandash25,26 | Udo Dannlowski13 | Giuseppe Delvecchio23 |
Ana M. Díaz-Zuluaga27 | Theo G. M. van Erp28,29 | Mar Fatjó-Vilas11 |
Sonya F. Foley30 | Katharina Förster13 | Janice M. Fullerton31,32 |
José M. Goikolea21 | Dominik Grotegerd13 | Oliver Gruber33 |
Bartholomeus C. M. Haarman34 | Beathe Haatveit3,2 | Tomas Hajek9,10 |
Brian Hallahan7 | Mathew Harris35 | Emma L. Hawkins35 | Fleur M. Howells36,37 |
Carina Hülsmann13 | Neda Jahanshad38 | Kjetil N. Jørgensen4,3 | Tilo Kircher39,40 |
Bernd Krämer33 | Axel Krug39,40,41 | Rayus Kuplicki42 | Trine V. Lagerberg2 |
Thomas M. Lancaster30,43 | Rhoshel K. Lenroot31,44,45 | Vera Lonning3,4 |
Carlos López-Jaramillo27,46 | Ulrik F. Malt6 | Colm McDonald7 |
Andrew M. McIntosh35 | Genevieve McPhilemy7 | Dennis van der Meer3,47 |
Ingrid Melle3,2 | Elisa M. T. Melloni16,17 | Philip B. Mitchell44,48 | Leila Nabulsi7 |
Igor Nenadic39,40 | Viola Oertel49 | Lucio Oldani22 | Nils Opel13 |
Maria C. G. Otaduy50 | Bronwyn J. Overs31 | Julian A. Pineda-Zapata51,27 |
Edith Pomarol-Clotet11 | Joaquim Radua52,53,54 | Lisa Rauer33 |
Ronny Redlich13 | Jonathan Repple13 | Maria M. Rive55 | Gloria Roberts44,48 |
Henricus G. Ruhe56,55,57 | Lauren E. Salminen38 | Raymond Salvador11 |
Salvador Sarró11 | Jonathan Savitz42,58 | Aart H. Schene57,56 | Kang Sim59,60,61 |
Marcio G. Soeiro-de-Souza62 | Michael Stäblein49 | Dan J. Stein36,37,63 |
Frederike Stein39,40 | Christian K. Tamnes2,4,3,64 | Henk S. Temmingh36,65 |
Unn K. Haukvik and Tiril P. Gurholt should be considered joint first authors.
Received: 13 May 2020 Revised: 18 September 2020 Accepted: 6 October 2020
DOI: 10.1002/hbm.25249
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2020 The Authors. Human Brain Mapping published by Wiley Periodicals LLC.
Hum Brain Mapp. 2020;1–14. wileyonlinelibrary.com/journal/hbm 1
Sophia I. Thomopoulos38 | Dick J. Veltman66,67 | Eduard Vieta68 |
Lena Waltemate13 | Lars T. Westlye2,69 | Heather C. Whalley35 |
Philipp G. Sämann70 | Paul M. Thompson38 | Christopher R. K. Ching38 |
Ole A. Andreassen3,2 | Ingrid Agartz3,4,71 | ENIGMA Bipolar Disorder Working Group
1Department of Adult Mental Health, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
2Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
3Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway
4Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway
5Department of Neurology, Oslo University Hospital, Oslo, Norway
6Institute of Clinical Medicine, University of Oslo, Oslo, Norway
7Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and
Health Sciences, National University of Ireland Galway, Galway, Ireland
8Institute of Medical Imaging & Visualisation, Faculty of Health & Social Sciences, Bournemouth University, Bournemouth, UK
9Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada
10National Institute of Mental Health, Klecany, Czech Republic
11FIDMAG Germanes Hospitalàries Research Foundation, CIBERSAM, Barcelona, Spain
12Institute of Clinical Radiology, University of Münster, Münster, Germany
13Department of Psychiatry, University of Münster, Münster, Germany
14Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, Australia
15The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Australia
16Psychiatry and Clinical Psychobiology, Scientific Institute Ospedale San Raffaele, Milan, Italy
17University Vita-Salute San Raffaele, Milan, Italy
18Deakin University, IMPACT, the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Victoria, Australia
19Orygen, The National Centre of Excellence in Youth Mental Health and Centre for Youth Mental Health, the Department of Psychiatry and the Florey Institute for
Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia
20Psychosomatic and CL Psychiatry, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
21Barcelona Bipolar Disorders and Depressive Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain
22Department of Neurosciences and Mental Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
23Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
24MRC Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
25Brain, Mind and Society Research Hub, Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria,
Australia
26Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Melbourne, Victoria, Australia
27Research Group in Psychiatry, Department of Psychiatry, Faculty of Medicine, Universidad de Antioquia, Medellín, Antioquia, Colombia
28Clinical Translational Neuroscience Laboratory, Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, California
29Center for the Neurobiology of Learning, University of California Irvine and Memory, Irvine, California
30Cardiff University Brain Research Imaging Centre (CUBRIC), Cardiff University, Cardiff, UK
31Neuroscience Research Australia, Randwick, New South Wales, Australia
32School of Medical Sciences, The University of New South Wales, Sydney, New South Wales, Australia
33Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University Hospital, Heidelberg, Germany
34Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
35Division of Psychiatry, University of Edinburgh, Edinburgh, UK
36Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, Western Cape, South Africa
37Neuroscience Institute, University of Cape Town, Cape Town, Western Cape, South Africa
38Imaging Genetics Center, USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of the University of Southern California,
Marina del Rey, California
39Department of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg, Germany
40Center for Mind, Brain and Behavior (CMBB), Marburg, Germany
2 HAUKVIK ET AL.
41Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany
42Laureate Institute for Brain Research, Tulsa, Oklahoma
43School of Psychology, Bath University, Bath, UK
44School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia
45University of New Mexico, Albuquerque, New Mexico
46Mood Disorders Program, Hospital Universitario San Vicente Fundación, Medellín, Antioquia, Colombia
47School of Mental Health and Neuroscience, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands
48Black Dog Institute, Sydney, New South Wales, Australia
49Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany
50LIM44, Department of Radiology and Oncology, University of S~ao Paulo, S~ao Paulo, Brazil
51Research Group, Instituto de Alta Tecnología Médica, Medellín, Antioquia, Colombia
52Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERSAM, Barcelona, Spain
53Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
54Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden
55Psychiatry, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands
56Donders Institute for Brain, Cognition and Behavior, Radboud University, Nijmegen, The Netherlands
57Department of Psychiatry, Radboudumc, Nijmegen, The Netherlands
58Oxley College of Health Sciences, The University of Tulsa, Tulsa, Oklahoma
59West Region/Institute of Mental Health, Singapore, Singapore
60Yong Loo Lin School of Medicine/National University of Singapore, Singapore, Singapore
61Lee Kong Chian School of Medicine/Nanyang Technological University, Singapore, Singapore
62Department of Psychiatry, Universidade de S~ao Paulo, S~ao Paulo, Brazil
63SA MRC Unit on Risk & Resilience in Mental Disorders, Department of Psychiatry & Neuroscience Institute, University of Cape Town, Cape Town, Western Cape,
South Africa
64PROMENTA Research Center, Department of Psychology, University of Oslo, Oslo, Norway
65General Adult Psychiatry Division, Valkenberg Hospital, Cape Town, Western Cape, South Africa
66Department of Psychiatry, Amsterdam UMC, Location VUMC, Amsterdam, The Netherlands
67Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands
68Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
69Department of Psychology, University of Oslo, Oslo, Norway
70Max Planck Institute of Psychiatry, Munich, Germany
71Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Institutet, Stockholm, Sweden
Correspondence
Unn K. Haukvik and Tiril P. Gurholt, Oslo
University Hospital, P.O. Box 4956 Nydalen,
0424 Oslo, Norway.
Email: u.k.h.haukvik@medisin.uio.no (U. K. H.)
and t.p.gurholt@medisin.uio.no (T. P. G.)
Funding information
Instituto de Salud Carlos III, FEDER
Funds/European Regional Development Fund,
Grant/Award Numbers: PI19/00394,
CPII19/00009; Departament de Salut de la
Generalitat de Catalunya, Grant/Award
Number: SLT002/16/00331; FAPESP;
Singapore Bioimaging Consortium, Grant/
Award Number: RP C-009/2006; NWO/
ZonMW VENI-Grant, Grant/Award Number:
016.126.059; Netherlands Organization for
Health Research and Development (ZonMw),
Program Mental Health, Education of
Investigators in Mental Health, Grant/Award
Number: 100-002-034; NIGMS, Grant/Award
Abstract
The hippocampus consists of anatomically and functionally distinct subfields that may
be differentially involved in the pathophysiology of bipolar disorder (BD). Here we,
the Enhancing NeuroImaging Genetics through Meta-Analysis Bipolar Disorder work-
inggroup, study hippocampal subfield volumetry in BD. T1-weighted magnetic reso-
nance imaging scans from 4,698 individuals (BD = 1,472, healthy controls
[HC] = 3,226) from 23 sites worldwide were processed with FreeSurfer. We used lin-
ear mixed-effects models and mega-analysis to investigate differences in hippocam-
pal subfield volumes between BD and HC, followed by analyses of clinical
characteristics and medication use. BD showed significantly smaller volumes of the
whole hippocampus (Cohen's d = −0.20), cornu ammonis (CA)1 (d = −0.18), CA2/3
(d = −0.11), CA4 (d = −0.19), molecular layer (d = −0.21), granule cell layer of dentate
gyrus (d = −0.21), hippocampal tail (d = −0.10), subiculum (d = −0.15), presubiculum
(d = −0.18), and hippocampal amygdala transition area (d = −0.17) compared to
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HC. Lithium users did not show volume differences compared to HC, while non-users
did. Antipsychotics or antiepileptic use was associated with smaller volumes. In this
largest study of hippocampal subfields in BD to date, we show widespread reductions
in nine of 12 subfields studied. The associations were modulated by medication use
and specifically the lack of differences between lithium users and HC supports a pos-
sible protective role of lithium in BD.
K E YWORD S
bipolar disorder subtype, hippocampus, large-scale, lithium, psychosis, structural brain MRI
1 | INTRODUCTION
Bipolar disorders (BD) affect over 1% of the population worldwide
(Grande, Berk, Birmaher, & Vieta, 2016). Clinical characteristics and
severity of the disorder vary; while some patients are disabled, others
live normal lives between mood episodes; some experience psychotic
episodes whereas others do not, and medication regimes and
responses differ widely. This clinical heterogeneity may hamper the
search for consistent underlying pathophysiological disease mecha-
nisms that remain elusive despite widespread research efforts.
Smaller hippocampal volumes have been reported in BD com-
pared to healthy controls (HC) in magnetic resonance imaging (MRI)
studies (Haukvik et al., 2015; Hibar et al., 2016). The hippocampus is a
key structure in the limbic system and is involved in multiple cognitive
functions including pattern separation/completion processes that con-
tribute to learning and episodic memory (Squire & Wixted, 2011),
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emotion regulation, as well as visuospatial orientation (Fanselow &
Dong, 2010). Of specific interest in BD, disrupted pattern separation
and completion processes are hypothesized to underlie the formation
of delusional thought content (Tamminga, Stan, & Wagner, 2010).
Importantly, the hippocampus consists of anatomically and functionally
distinct subfields that may be differentially involved in the pathophysi-
ology of the disorder. Post mortem neuropathological investigations of
individuals with BD show lower nonpyramidal somal volume in the
cornu ammonis (CA) 2/3 region (Konradi et al., 2011) and fewer inter-
neurons in the parasubiculum (Wang et al., 2011) region. Furthermore,
individuals with BD show greater neuronal counts in the CA1 and sub-
iculum and higher CA1 oligodendrocyte counts compared to HC
(Malchow et al., 2015). Other postmortem studies have reported nega-
tive findings (Harrison, Colbourne, & Harrison, 2020), which highlights
a lack of consensus and need for more precise interrogation.
MRI studies of hippocampal subfield volumetry in BD have been
inconsistent (Haukvik, Tamnes, Soderman, & Agartz, 2018). Among the
two largest studies to date (each comprising approximately 200 individ-
uals with BD and 300 HC), one study reported smaller volumes in the
CA2/3, CA4/dentate gyrus (DG), presubiculum, and subiculum
(Mathew et al., 2014), and the other reported smaller CA2/3, CA4/DG,
subiculum, and CA1, but no detectable abnormalities in presubiculum
volume (Haukvik et al., 2015) in BD compared to HC, respectively. Fur-
thermore, subfield volume reductions in the left CA4, granular cell layer
of the DG, molecular layer, and bilateral tail volumes were reported
more pronounced in BD1 than BD2 participants (Cao et al., 2017).
Although limited, such evidence suggests that differentiation in sub-
field hippocampal volumetry may depend on BD subtypes. Hippocam-
pal subfield volumes may also be affected by medication use. Lithium
treatment has been associated with less pronounced volume deficien-
cies in CA2/3, CA4/DG and subiculum (Haukvik et al., 2015; Mathew
et al., 2014), and CA1 (Hartberg et al., 2015). Stem cell research has
shown that lithium increases progenitor cell proliferation in the DG,
lending support to the possible neuroprotective and neurotrophic
effects of lithium inferred from other MRI studies (Ferensztajn-
Rochowiak & Rybakowski, 2016). Increased angiogenesis and neuro-
genesis in the DG have been associated with the use of antidepressant
medications (selective serotonin reuptake inhibitors) in individuals with
major depressive disorder (Boldrini et al., 2012). Antipsychotic medica-
tion use has been linked to elevated hippocampal neurogenesis
(olanzapine) and increased cell-proliferation (clozapine) (Balu &
Lucki, 2009), but the results on hippocampal volume from human MRI
(Bodnar et al., 2016) and animal (Crum et al., 2016; Schmitt, Weber,
Jatzko, Braus, & Henn, 2004) studies are inconclusive.
Given the small size of the hippocampal subfields, it is challenging
to obtain valid and reliable hippocampal subfield volume estimates
from automated MRI-based processing tools. Recently, by combining
cyto- and chemo-architectural features with macroscopic landmarks,
segmentation of the hippocampal subfields from MR-images has
improved, and high-resolution ex-vivo data have been used to
develop detailed hippocampal subfield atlases (Iglesias et al., 2015),
which have proven stable across scanners and time points (Brown
et al., 2020). Despite such advances and the refinement of automated
segmentation protocols (Iglesias et al., 2015; Pipitone et al., 2014;
Yushkevich et al., 2010; Yushkevich et al., 2015) it remains challenging
to reproduce findings across studies (Haukvik et al., 2018). This dis-
crepancy could reflect differences in clinical characteristics, but also
methodological differences between segmentation algorithms
(e.g., discrepancies in subfield delineation which may yield different
volume estimates), field strength differences (1.5T, 3T, or higher) and
the use of T1 and/or T2 weighted images (Mueller et al., 2018).
The Enhancing Neuro Imaging Genetics through Meta-Analysis
Bipolar Disorder (ENIGMA BD) Working Group has brought BD
researchers together from around the world to address the limitations
of previous smaller scale MRI studies. More recently, ENIGMA groups
have moved beyond cohort level meta-analyses to pooled, or “mega”-
analyses, where anonymized and unidentifiable individual-level data are
aggregated in a central location, allowing more flexible statistical design
(Boedhoe et al., 2018). By applying publicly available, harmonized pro-
tocols across retrospective samples, mega-analyses become feasible,
offering benefits over meta-analyses of studies based on different
processing/analysis methodologies (Boedhoe et al., 2018). We previ-
ously reported on smaller whole hippocampal volumes in BD compared
to HC (Hibar et al., 2016), and in other psychiatric disorders including
major depressive disorder (Schmaal et al., 2016), and schizophrenia
(van Erp et al., 2016). Moreover, prior studies (Cao et al., 2017; Haukvik
et al., 2015; Mathew et al., 2014) of hippocampal subfield volumes in
BD used a previous version of the FreeSurfer segmentation algorithm
(Van Leemput et al., 2009), and a subsequent meta-analysis (Haukvik
et al., 2018) did not allow for analyses of individual medication effects.
Here we extend previous studies by using an individual mega-analytic
approach and a newer more anatomically robust hippocampal subfield
FreeSurfer segmentation algorithm to determine whether alterations in
specific hippocampal subfields can explain the previously reported
lower overall hippocampal volume in BD. By this, we also address the
need for replication of neuroimaging studies in clinical samples (Open
Science Collaboration, 2015; Thompson et al., 2020). We include sec-
ondary analyses of the effects of diagnostic subtype, medication use,
and clinical characteristics on hippocampal subfield volumes. In the
largest study to date—with pooled data from over 4,600 participants—
we hypothesized a robust pattern of lower hippocampal subfield vol-
umes in individuals with BD compared to HC. These deficits were
expected to be more severe in BD1 than in BD2. We also expected to
find evidence for neuroprotective effects of lithium. Determining the
specific pattern of subfield volume reduction in BD may provide further
insights into the pathophysiological mechanisms of the disorder.
2 | METHODS AND MATERIALS
2.1 | Subject samples
The ENIGMA BD hippocampal subfields project included MRI data and
clinical characterization of 4,698 subjects (57% female) from 23 sites
worldwide (27 scanners), with n = 1,472 individuals with BD (60%
female) and n = 3,226 HC (56% female). BD diagnoses were assessed
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according to the Diagnostic and Statistical Manual of Mental Disorders,
fourth version (DSM-IV) or the International Statistical Classification of
Diseases and Related Health Problems, 10th Revision (ICD-10). The
sample was split into BD1 (n = 1,079, 58% female) or BD2 (n = 353,
65% female) for DSM-IV classified patients. The age range was
18–70 years. Current psychotic symptoms were assessed with the Pos-
itive and Negative Symptoms Scale (PANSS). Lifetime psychosis was
obtained as a yes/no variable across sites. Clinical and demographic
information, as well as estimated current medications are presented in
Table 1, whereas site-specific information is shown in Table S1.
All subjects provided written informed consent and all participat-
ing sites obtained prior approval from their local ethics committees
and institutional review boards, including approval to share
anonymized data. The study was conducted in accordance with the
Helsinki declaration.
2.2 | Image processing and analysis
Structural T1-weighted brain MRI scans were obtained at 23 sites fol-
lowing locally optimized scanner protocols. The majority of scans
were acquired on 3T scanners (n = 21 scanners/3,766 scans) and the
remaining were scanned at 1.5T (n = 6 scanners/932 scans), with all
diagnostic groups represented across field strengths. Image acquisi-
tion parameters for each site are provided in Table S2. Images were
processed locally with the automated and validated FreeSurfer soft-
ware (http://www.freesurfer.net) following standardized ENIGMA
protocols for harmonization and quality control across multiple sites
(http://enigma.ini.usc.edu; Note S1). Subfield volumes were obtained
using the hippocampal subfield segmentation algorithm in FreeSurfer
v 6.0.0 (Iglesias et al., 2015) based on information from manual delin-
eations of ultrahigh resolution (0.1 mm isotropic) ex vivo MRI data.
We obtained volumes for 12 subfield regions (CA1, CA2/3, CA4,
molecular layer, granule cell layer of the dentate gyrus (GC ML DG;
FreeSurfer naming convention), hippocampal tail, subiculum,
presubiculum, parasubiculum, fimbria, hippocampal fissure, and the
hippocampal amygdala transition area (HATA)), the whole hippocam-
pus, and estimated intracranial volume (ICV). The segmented volumes
were assessed for outliers at each site following standardized
ENIGMA protocols. Any outlier volumes were visually inspected and
removed if the segmentation quality was judged to be inadequate
(Note S1).
TABLE 1 Demographic and clinical information
Cases (N = 1,472) Controls (N = 3,226)
N % N % χ2/Wilcoxon rank-sum test p-Value
Females (%) 884 60.1 1,793 55.6 8.1 .0045
Mean SD Mean SD
Age (years)a 37.9 11.9 33.3 11.2 4.6 <.001
AOO (years)b 23.2 9.3
DOI (years)b 15.1 10.8
PANSS positivec 9.1 3.1
PANSS negatived 9.4 3.3
N N
Lifetime psychosise 403/369/700
BD1/BD2/BD-NOSf 1,079/353/36
Medication
Lithiume 363/749/360
Antipsychoticse 549/614/309
Antiepilepticse 363/495/614
Antidepressantse 278/580/614
Scanner field strength
1.5T; BD (BD1/BD2/BD-NOS); HC 436 (337/88/10) 496
3T; BD (BD1/BD2/BD-NOS); HC 1,036 (742/265/26) 2,730
Abbreviations: AAO, age at onset; DOI, duration of illness; BD, bipolar disorder; HC, healthy controls; NOS, not otherwise specified; PANSS, Positive and
Negative Syndrome Scale.
aNot normal—applied two-sided Wilcoxon rank sum test.
bTwo hundred and nineteen patients with missing AAO/DOI.
cNine hundred and sixty-two patients missing PANSS positive score.
dNine hundred and sixty-four patients missing PANSS negative score.
eYes/no/missing.
fFour patients missing diagnostic category (BD1, BD2, BD.NOS).
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2.3 | Statistical analyses
All statistical analyses were performed in R (version 3.5.2; http://R-
project.org). Group differences in demographic and clinical variables
were assessed with chi-squared tests for categorical data and t-tests/
Wilcoxon rank-sum tests (Note S2) for normally/non-normally distrib-
uted continuous data, respectively. To assess the normality of distri-
butions, we used the Shapiro–Wilk normality test. We also evaluated
the distribution of the participants' whole hippocampus and hippo-
campus subfield volumes for normality (Figures S1 and S2).
Individual tabular data from all sites were pooled on a secure
server at the University of Oslo for centralized analysis. For the main
case–control analysis, a linear mixed-effects (LME) model was used to
assess diagnostic differences in the whole hippocampus and hippo-
campal subfields volumes, with sex, age, age2, sex*age, sex*age2, and
ICV as fixed-effects variables, and with scanner nested in field
strength as random-effects variables. We included the age2 term
because the hippocampus shows a nonlinear age-related trajectory
with accelerating atrophy at more advanced age (Fjell et al., 2013).
We used the lme-function from the nlme-package to fit the LME
models. Because the left and right hemisphere subfield volumes were
highly correlated, and we did not have an a priori hypothesis on
laterality, the left and right hemisphere volumes of each subfield were
combined (summed) in order to reduce the number of tests and
increase statistical power. For completeness, we investigated the
model for each hemisphere separately. We also performed analyses
with field strength added as a fixed factor to address possible con-
founding effects of field strength on the volume results.
Follow-up analyses of BD1 versus BD2 subgroup differences
were performed using similar LME models that included sex, age,
age2, sex*age, sex*age2, and ICV as fixed-effects variables, and scan-
ner nested in fields strength as random-effects variables. Firstly, we
compared BD1 and BD2 to each other, and then secondly, we com-
pared each BD subtype to HC in separate analyses, unless otherwise
stated. We used this approach to determine the effects of lifetime
psychosis (i.e., the occurrence of any episode of psychosis during
mood episodes throughout life), which cuts across the BD1/BD2 cate-
gorization. In separate analyses, we analyzed associations between
current positive or negative psychotic symptoms, duration of illness,
age at illness onset and subfield volumes among patients only, while
adjusting for BD1/BD2 categorization. Finally, within individuals with
BD1, we analyzed the effects of current medication use for each
group of medication (i.e., lithium, antipsychotics, antidepressants, or
antiepileptics), and performed a joint examination of the effects of all
medication groups. Current medication use was stratified into users/
non-users based on the available medication data from each site and
for each group of medication. In the first set of medication analyses,
we directly compared medication users with non-users. In the second
set of medication analyses, users and non-users were separately com-
pared to HC. We limited the joint examination of all medication
groups to patients only. Medication analyses were restricted to the
BD1 group to avoid potential confounding effects of the different
medication regimes, clinical characteristics, and hippocampal
volumetry associated with BD1 and BD2. We did not perform sepa-
rate medication analyses in the BD2 group, as it was smaller and had
limited information on medication.
We computed Cohen's d effect size estimates from the t-statistics
from the LME models (Nakagawa & Cuthill, 2007). To adjust for multi-
ple comparisons, Bonferroni correction for N tests with α = .05 was
applied, where N is the number of tests for the combined right and
left hemisphere subfields (and whole hippocampus) which gives a sig-
nificance threshold at p = .0038 (13 tests). We used forest plots to
visualize possible site differences (Note S3).
3 | RESULTS
3.1 | Demographic variables
The BD group was significantly older (Δ = 4.6/p< .001) and included
more women (χ2 = 10.8/p = .0045) than the HC group. Demographic
and medication information are listed in Table 1 and shown in
Figure S3 (for site-specific information see Table S1).
Among the individuals with BD1 included in the medication ana-
lyses, 165 received antipsychotics, 151 received lithium, 42 received
antiepileptics, and 28 received antidepressants. In addition,
168 received lithium in combination with antipsychotics, antiepilep-
tics, antidepressants, or a combination of the three, and 196 received
antipsychotics, antiepileptics and/or antidepressants in different com-
binations (Figure S4 for details). Demographic variables for the BD1
group are listed in Table S3.
3.2 | Bipolar disorder versus healthy control
differences in hippocampus subfield volumes
In the main LME analysis, individuals with BD showed significantly
smaller whole hippocampus volume (Cohen's d = −0.20, p = 3.1e−10)
compared to HC (Figure 1a, Table S4). Smaller volumes were present
across most subfields, including the hippocampal tail, subiculum,
presubiculum, CA1, CA2/3, CA4, molecular layer, GC ML DG, and
HATA, with the largest effect sizes for the molecular layer (d = −0.21)
and GC ML DG (d = −0.21). Split hemisphere analyses showed a simi-
lar pattern of subfield volume reductions in the left and right hippo-
campus (Figure S5a). Forest plots illustrate the patterns of subfield
volume reductions across sites (Figure S6). The introduction of a fixed
term for field strength resulted in no significant effect for the latter
and did not alter the group analysis results from the main model (data
not shown).
3.3 | Bipolar disorder subtype and clinical
characteristics effects on subfield volume
Follow-up analyses of BD-subtypes showed no significant volumetric
differences between BD1 and BD2 for the whole hippocampus or any
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of the subfields (Table S5). Smaller whole hippocampus volume was
found in BD1 (Cohen's d = −0.22, p = 8.9e−11) but not BD2
(d = −0.11, nominally significant) compared to HC (Figure 1b;
Table S6a). In BD1, volumes were smaller across most subfields,
including the hippocampal tail, subiculum, presubiculum, CA1, CA2/3,
CA4, molecular layer, GC ML DG, and HATA. The effect sizes were
slightly larger than in the main analysis (including all BD subtypes),
with the largest effects for the GC ML DG (d = −0.23) and molecular
layer (d = −0.23). In BD2, there were nominally significant findings for
CA1, CA4, GC ML DG, and molecular layer volumes when compared
to HC. Split hemisphere analyses showed a similar pattern of subfield
volume alterations for both hemispheres (Figure S5b; Table S6b,c).
Forest plots of BD1 and BD2 subfield volumes when compared to HC
also showed differences across sites (Figures S7 and S8).
In follow-up analyses of the whole BD group, patients with and
without a history of lifetime psychosis (available in 403 patients ver-
sus 369 without) both showed similar effect patterns compared to
HC across subfield volumes (Figures 2 and S9; Table S7). Current
psychosis symptoms, age at onset, and illness duration were not
associated with any of the hippocampal subfield volumes
(Tables S8–S11).
3.4 | Medication effects
Individuals with BD1 taking lithium at the time of scan (n = 319)
showed significantly larger volumes for the whole hippocampus
(d = 0.22, p = .0028), molecular layer (d = 0.23), GC ML DG (d = 0.22),
and smaller hippocampal fissure (d = −0.24), compared to those not
taking lithium (n = 464) after applying Bonferroni correction
(Table S12). Individuals with BD1 and taking lithium did not show sig-
nificant volume differences in any subfield or for the whole hippocam-
pus compared to HC. Conversely, individuals with BD1 who were not
on lithium showed significant volume reductions compared to
HC. Importantly, the effect sizes from the BD1-nonlithium versus the
HC analysis were greater than the effect sizes from the main analysis
comparing all BD subjects with HC, with largest effect sizes for the
molecular layer (d = −0.32), GC ML DG (d = −0.30), CA1 (d = −0.27),
CA4 (d = −0.27), presubiculum (d = −0.28), and whole hippocampus
(d = −0.31) (Figure 3; Table S13). These effects were similar bilaterally
(Figure S10).
Among individuals with BD1, antipsychotics users (n = 472)
showed significantly smaller presubiculum volume than antipsychotics
non-users (n = 385) (d = −0.24, p = 7e−04) (Table S14). Significant
F IGURE 1 Hippocampal subfield volume differences between patients with bipolar disorder and healthy controls. Notes: (a) all bipolar
disorder patients compared to healthy controls, (b) patients with bipolar 1 (n = 1,079) and bipolar 2 (n = 353) compared to healthy controls.
Significant differences indicated by *. CA3 implies CA2/3. CA, cornu ammonis; GC ML DG, granule cell layer of dentate gyrus; HATA,
hippocampal amygdala transition area; HP, hippocampus
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volume reductions were found across subfields in individuals with
BD1 who used antipsychotics relative to HC, with largest effects in
presubiculum (d = −0.3), molecular layer (d = −0.28), GC ML DG
(d = −0.27), and CA4 (d = −0.24) (Figure S11a; Table S15) and these
effects were bilateral (Figure S12a). Individuals with BD1 who did not
use antipsychotics had smaller volumes of the GC ML DG (d = −0.16)
and CA4 (d = −0.15) compared to HC. The effect sizes for the volume
reductions were larger in individuals with BD1 who used antipsy-
chotics than in non-users, when compared to HC.
Individuals with BD1 who used antiepileptics (n = 256) had signifi-
cantly smaller hippocampal tail (d = −0.25) volumes compared to indi-
viduals with BD1 who did not use antiepileptics (n = 309) (Table S16).
Compared to HC, both individuals with BD1 who used and who did
not use antiepileptics showed volume alterations similar to those
detected with the main model (All BD versus HC)—with larger effect
sizes among individuals with BD1 who used antiepileptics
(Figures S11b and S12b; Table S17).
Antidepressant use was not associated with specific subfield vol-
ume differences among individuals with BD1 (Table S18), and both
antidepressant users (n = 155) and nonusers (n = 410) showed a simi-
lar pattern of smaller subfield volumes compared to HC (Figures S11c
and S12c; Table S19).
Finally, to better understand the potential medication effects in
individuals on more than one medication at the time of scan, a model
in which all medications were included as fixed covariates was used to
determine the potential effect of each medication while controlling
for all other medications. We had complete medication information
for a subset of individuals with BD1 (n = 565), of which n = 53 were
unmedicated at the time of scanning. Of the medicated patients
(n = 512), there were n = 181 lithium users, n = 343 antipsychotics
users, n = 155 antiepileptics users, and n = 256 antidepressant users
in different combinations (see Figure S13 for details). Antipsychotics
users showed significantly smaller presubiculum volume (d = −0.28)
compared to non-users when adjusting for lithium, antiepileptics, and
antidepressant use. No other medication showed a significant volume
effect when simultaneously adjusting for all other medications
(Table S20).
F IGURE 2 Hippocampal subfield volume differences between
bipolar disorder patients with or without a lifetime history of
psychosis, and healthy controls. Notes: Bipolar patients with (n = 403)
and without (n = 369) a diagnosis of lifetime psychosis compared to
controls. Significant differences indicated by *. CA3 implies CA2/3.
CA, cornu ammonis; GC ML DG, granule cell layer of dentate gyrus;
HATA, hippocampal amygdala transition area; HP, hippocampus
F IGURE 3 Hippocampal subfield volume differences between
lithium users and nonusers among bipolar disorder 1 patients, and
healthy controls. Notes: Bipolar 1 lithium users (n = 319) and nonusers
(n = 464) compared to healthy controls (reference). Significant
structures indicated by *. CA3 implies CA2/3. CA, cornu ammonis; GC
ML DG, granule cell layer of dentate gyrus; HATA, hippocampal
amygdala transition area; HP, hippocampus
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4 | DISCUSSION
This largest study of hippocampal subfield volumes in BD to date, had
five key findings: (a) individuals with BD had smaller volumes across
most subfields compared to HC, (b) individuals with the BD1 subtype
showed largest effect sizes when compared to HC, (c) volumes in lith-
ium users did not differ from HC, (d) antipsychotics and antiepileptics
users showed smaller volumes compared to non-users, and (e) altered
volumes were not associated with other clinical characteristics. By
pooling data sets to include over 4,600 participants, these results con-
firm and extend our current knowledge of hippocampal struc-
ture in BD.
The main finding of smaller subfield volumes across the hippo-
campal subfields in BD is partly in line with the results from prior stud-
ies (Cao et al., 2017; Haukvik et al., 2015; Mathew et al., 2014) and
one meta-analysis (Haukvik et al., 2018). In accordance with previous
heterogeneous results, the forest plots demonstrate a high degree of
heterogeneity across the included sites, which may help explain the
disparate findings across prior studies. We found largest effect sizes
for volume differences between BD and HC for the molecular layer,
presubiculum, GC ML DG, CA4, and CA1, in line with previous find-
ings (Haukvik et al., 2018). The molecular layer was not delineated as
an independent structure in the earlier version of the FreeSurfer hip-
pocampal subfield segmentation algorithm (Van Leemput et al., 2009),
which was used in most prior studies. However, Cao et al. found
smaller molecular layer volumes in BD with the same subfield segmen-
tation as used in the present study (Cao et al., 2017). The molecular
layer stretches as a dark band from the DG along the CA subfields to
the subiculum. It is relatively cell free (Iglesias et al., 2015) but con-
tains dendrites from DG neurons (Amaral, Scharfman, &
Lavenex, 2007). We may speculate that the smaller molecular layer
could reflect loss of dendritic connections or DG neurons of which
hyperexcitability has been linked to successful lithium treatment in
BD (Mertens et al., 2015; Stern et al., 2018). Some (Mathew
et al., 2014), but not all (Cao et al., 2017; Haukvik et al., 2015), prior
studies have reported smaller presubiculum volumes in BD. The
presubiculum is part of the outflow region of the hippocampus—
together with the parasubiculum and the more well-defined subiculum
subfields—and is involved in visuospatial processing and orientation
(Dalton & Maguire, 2017; Simonnet et al., 2017). As expected from
prior findings, individuals with BD also showed lower volumes in the
CA4, CA1, GC ML DG, and in the subiculum (Haukvik et al., 2018).
Finally, we found significantly lower CA2/3 volume in BD, as hypothe-
sized on the basis of previous studies (Cao et al., 2017; Haukvik
et al., 2015; Mathew et al., 2014) and the presumed role of this sub-
field in the pattern completion thought to underlie the formation of
psychotic thought content (Tamminga et al., 2010).
We found that the effect sizes for the case–control volume dif-
ferences across the hippocampus were larger in BD1 than BD2. This
is in line with the results from Cao et al. (2017), and may suggest a
stronger hippocampus related neurobiological component in BD1
than in BD2. However, given the lack of significant differences in the
direct BD1 versus BD2 comparison, it could also reflect the smaller
number of individuals with BD2. The BD2 results may also be con-
founded by the greater clinical heterogeneity that is displayed by the
BD2 compared to the BD1 subtype (Phillips & Kupfer, 2013).
Medication use, in particular the use of lithium, was associated
with the subfield volumes across the hippocampus, which confirms
and extends results from prior studies (Bearden et al., 2008; Hartberg
et al., 2015; Simonetti et al., 2016). Lithium users did not show signifi-
cant volume deficiencies compared to healthy controls, whereas the
nonusers did. These results may reflect a neuroprotective effect of
lithium on hippocampal subfield volumes, which is in line with previ-
ous whole brain MRI volumetric studies (Berk et al., 2017). In accor-
dance with this understanding are also animal studies showing
enhanced neural proliferation (Zanni et al., 2017), stem cell studies
showing increased progenitor cell proliferation (Ferensztajn-
Rochowiak & Rybakowski, 2016), the increased numbers of neurons
and glia in the DG (Rajkowska et al., 2016) following lithium use
shown in postmortem studies. Furthermore, we observed that anti-
psychotic or antiepileptic medication use was associated with smaller
subfield volumes, and the effects of antipsychotic use on the
presubiculum volume remained significant after controlling for all
other psychopharmacological use. The smaller volumes are consistent
with previous BD studies showing a negative association between
antipsychotics or antiepileptics and neurostructural measures (Fusar-
Poli et al., 2013; Hibar et al., 2016). Antipsychotics have been shown
to increase hippocampal neurogenesis and cell proliferation (Balu &
Lucki, 2009), but the effects on hippocampal volumes from human
MRI (Bodnar et al., 2016) and animal (Crum et al., 2016; Schmitt
et al., 2004) studies have been mixed. Our results, taken together with
the lack of an association between duration of illness, current or life-
time psychosis, or age at illness onset on any of the subfield volumes,
may suggest that putative neurogenic and cell-proliferative effects of
antipsychotic medication were not large enough to affect hippocam-
pal subfield volumes. We did not observe any association between
subfield volumes and anti-depressant medication, despite previous
reports of subfield-volume enlargement in patients with major depres-
sive disorder after selective serotonin reuptake inhibitor or serotonin
nor-adrenalin reuptake inhibitor treatment (Katsuki et al., 2020; Maller
et al., 2018). This could be due to confounding by other medication
use or symptom pathophysiology or severity characteristics within
our sample.
Certain limitations of our study should be noted. We were not
able to control for possible confounding factors such as alcohol or
substance abuse, IQ, number of depressive or manic episodes, or cur-
rent mood state, as these variables were only available for some sub-
sets of the participants and were not directly comparable as they
were obtained with different cognitive- and psychometric tests. We
could not control for socioeconomic status or childhood trauma, or
other comorbid brain disorders, which may also influence hippocampal
volume (Aas et al., 2014; Teicher, Anderson, & Polcari, 2012). Medica-
tion effects were studied in current users versus current non-users
since information on treatment duration or dosages was not available.
Information on current medication status was only available in a sub-
sample, which reduced the power to detect differences among BD1
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patients when stratified on medication group. The multisite MRI
acquisition invariably includes the use of different scanners and scan-
ning parameters, as well as different field strengths (1.5T and 3T). We
only had available T1-weighted MRI data, and a combination of T1-
and T2-weighted MRI data has been reported to increase segmenta-
tion accuracy (Iglesias et al., 2015). All participating sites included both
BD patients and HC (except for the Medellín, one of the Deakin sites,
and both Milan sites, which lacked HC). We controlled for scanners
and magnetic field strengths by including them as random-effects in
the model, which may not fully account for differences across sites.
While standardized processing pipelines have been shown to reduce
cross-site variability, true cross-site harmonization is only possible
through coordinated prospective data collection.
Major strengths of this study include the large sample size, the
use of ENIGMA-standardized processing pipelines to derive hippo-
campal subfield volumes across sites, and the mega-analysis of pooled
data. This study design helps to overcome some of the key limitations
of classic, literature-based meta-analyses (e.g., the combination of
effect sizes from studies that may differ widely with respect to
processing and analysis methodology) and previous smaller-scale stud-
ies with limited statistical power (Paulus & Thompson, 2019; Westlye,
Alnaes, van der Meer, Kaufmann, & Andreassen, 2019). By pooling
standardized brain measures across a diverse set of BD neuroimaging
studies, we have created a more ecologically valid cohort, which may
provide a more replicable picture of hippocampal subfield alterations
in BD as the illness presents around the world.
In conclusion, lower overall hippocampal volumes in BD were
traced to smaller volumes across the majority of the hippocampal sub-
fields. The effects were largest in the BD1 group, not specific to cur-
rent or lifetime psychosis, and influenced by medication use. The lack
of detectable group differences between lithium users and HC sup-
ports the notion of a possible neuroprotective role of lithium in
BD. These results demonstrate the power of large-scale multisite
efforts to disentangle clinical and methodological heterogeneity and
address the need for replication studies. Given the overlapping find-
ings of lower whole hippocampal volumes in the largest neuroimaging
ENIGMA studies of BD (Hibar et al., 2016), major depression (Schmaal
et al., 2016), and schizophrenia (van Erp et al., 2016), further studies
of hippocampal subfields may allow for neurobiological differentiation
across major mental illnesses.
ACKNOWLEDGMENTS
ENIGMA Core: NIH grant U54 EB020403 from the Big Data to Knowl-
edge (BD2K) Program; R01MH117601, R01AG059874;
T32AG058507; 5T32MH073526. TOP: The Research Council of Nor-
way (grant numbers 223273, 213700, 250358, 288083); KG Jebsen
Stiftelsen; South-Eastern Norway Regional Health Authority (grant
number 2017097; 2017112). NUI Galway: Funded by the Health
Research Board (HRA-POR-324) awarded to Dara M. Cannon, PhD.
Dalhousie: The Halifax studies were supported by funding from the
Canadian Institutes of Health Research (103703, 106469, and
142255), Nova Scotia Health Research Foundation, Dalhousie Clinical
Research Scholarship to T. Hajek, Brain & Behavior Research
Foundation (formerly NARSAD); 2007 Young Investigator and 2015
Independent Investigator Awards to T. Hajek. Deakin University:
Supported by an unrestricted grant from AstraZeneca. MB is
supported by a National Health and Medical Research Council
(NHMRC) Senior Principal Research Fellowship (1059660 and
APP1156072). FIDMAG: Generalitat de Catalunya: 2017SGR1271;
Instituto de Salud Carlos III (co-funded by the European Regional
Development Fund/European Social Fund): MSII16/00018,
CD16/00264, CD18/00029, PI18/00810, and PI18/00877. Milan: PB
was partially supported by a grant from the Italian Ministry of Health
(RF-2016-02364582). Cardiff: Recruitment was supported by the
National Centre for Mental Health (NCMH) funded by the Health and
Care Research Wales and the Bipolar Disorder Research Network
(BDRN), and funded through seedcorn funding from Cardiff University
and a NARSAD Young Investigator Award to XC (ref. 17319). MNC:
Funded by the German Research Foundation (SFB-TRR58, Project
C09 to UD) and the Interdisciplinary Center for Clinical Research
(IZKF) of the Medical Faculty of Münster (grant Dan3/012/17 to UD
and grant SEED11/18 to NO). Muenster: Funded by the German
Research Foundation (DFG), Udo Dannlowski (co-speaker FOR2107;
DA 1151/5-1, DA 1151/5-2). Marburg: Funded by the German
Research Foundation (DFG), Tilo Kircher (speaker FOR2107; DFG
grant numbers KI 588/14-1, KI 588/14-2), Axel Krug (KR 3822/5-1,
KR 3822/7-2), Igor Nenadic (NE 2254/1-2), Carsten Konrad
(KO 4291/3-1). Medellín/GIPSI: Supported by PRISMA UT—
Colciencias and Convocatoria Programática Ciencias de la Salud
2014-2015 by CODI-Universidad de Antioquia U de A. OUS: The
Research Council of Norway; South-Eastern Norway Regional Health
Authority (2014097); Oslo University Hospital—Rikshospitalet; the
Ebbe Frøland Foundation; a research grant from Mrs. Throne-Holst.
Sydney/UNSW: Supported by the Australian National Medical and
Health Research Council (Program Grant 1037196; Project Grants
1066177 and 1063960), and the Lansdowne Foundation. We also
acknowledge the Janette Mary O'Neil Research Fellowship (to JMF).
CLING/HMS: The CliNG study sample was partially supported by the
Deutsche Forschungsgemeinschaft (DFG) via the Clinical Research
Group 241 “Genotype-phenotype relationships and neurobiology of
the longitudinal course of psychosis,” TP2 (PI Gruber; http://www.
kfo241.de/ GR 1950/5-1). Groningen: Funded by EU-FP7-HEALTH-
222963 “MOODINFLAME” and EU-FP7-PEOPLE-286334 “PSY-
CHAID”. BFS: Supported by IMAGEMEND, which received funding
from the European Community's Seventh Framework Program
(FP7/2007-2013) under grant agreement no. 602450. This article
reflects only the author's views and the European Union is not liable
for any use that may be made of the information contained therein.
Also supported by a Wellcome Trust Strategic Award 104036/Z/14/
Z. Cape Town: Supported by the National Research Foundation,
South Africa and University Research Committee, University of Cape
Town. LIBR: Supported by the William K Warren Foundation, the
NIMH: R21MH113871, and the NIGMS: P20GM121312. Frankfurt:
Received no specific grant from any funding agency, commercial or
not-for-profit sectors. Amsterdam: Netherlands Organization for
Health Research and Development (ZonMw), Program Mental Health,
HAUKVIK ET AL. 11
Education of Investigators in Mental Health (OOG; #100-002-034).
NWO/ZonMW VENI-Grant #016.126.059. Singapore: Funded by the
Singapore Bioimaging Consortium (RP C-009/2006) research grant
awarded to Kang Sim. USP 3T: FAPESP. Hospital Clínic: FIS, PERIS,
ISCIII. PERIS grant from Departament de Salut de la Generalitat de
Catalunya (SLT002/16/00331). Miguel Servet II Research Contract
(CPII19/00009) and Research Project (PI19/00394) from Instituto de
Salud Carlos III, FEDER Funds/European Regional Development
Fund—a way to build Europe. Hippocampal Subfield Protocol Develop-
ment Team: Dr. van Erp reports funding by U54EB020403 and
R01MH116147. Milan-2: Italian Ministry of Health grant RF-
2011-02350980.
This work was performed on Services for sensitive data (TSD), IT-
department (USIT), University of Oslo, Norway, with resources pro-
vided by UNINETT Sigma2—the National Infrastructure for High Per-
formance Computing and Data Storage in Norway.
DISCLOSURE OF INTERESTS
UKH, TPG, SN, TNA, TH, MA, DA, DMC, SA, JB, BTB, FB, FB, CMB,
PB, EJC, XC, OD, UD, GD, AMD, MF, SFF, KF, JMF, JMG, DG, OG,
BCH, BH, BH, MAH, ELH, FMH, CH, KNJ, TK, BK, AK, RK, TVL, TML,
RKL, VL, CLJ, CM, EMTM, GM, IM, PBM, LN, IN, VO, LO, NO, MCO,
BJO, JAP, EP, JR, LR, RR, JR, MMR, GR, HGR, LES, RS, SS, JS, AHS,
KS, MGS, MS, FS, CKT, HST, SIT, DvdM, DJV, TGMvE, EV, LW, LTW,
HCW, PGS, and IA declare no conflicts of interest.
MB: was supported by an unrestricted grant from AstraZeneca;
TE, UFM, EB: has received speaker's fees from Lundbeck AS, and
Janssen Cilag; NJ, PMT: MPI of a research grant from Biogen, Inc. for
work unrelated to the contents of this manuscript; CRKC: is partially
funded by a Biogen Grant (to NJ and PMT) for research unrelated to
the contents of this manuscript. DJS: has received research grants
and/or honoraria from Lundbeck and Sun; OAA: has received
speaker's honorarium from Lundbeck, and is a consultant to Health-
Lytix. AMM: has received research support from Eli Lilly, Janssen, and
the Sackler Foundation, and has also received speaker fees from
Illumina and Janssen. All other authors report no biomedical financial
interests or potential conflicts of interest.
AUTHOR CONTRIBUTIONS
Cohort PI: BTB, FB, DMC, XC, UD, TE, OG, BCMH, TH, FMH, TK, AK,
CLJ, AM, IM, PBM, IN, EP, RS, JS, KS, MGS, EV, HCW, AMM, OAA,
IA. Project development: UKH, TPG, SN, MA, SA, BTB, UD, MF, JMF,
NJ, TK, RKL, VL, EP, RS, SS, HST, SIT, PMT, CRKC, IA. Imaging
methods: PGS, UKH, TPG, SN, NJ. Illustrations: TPG. Data interpreta-
tion: UKH, TPG, FB, UD, KF, DG, TH, CH, BK, NO, RR,
LW. Manuscript preparation: UKH, TPG, RR, CRKC, OAA, IA. Imaging
Data collection: UKH, SN, TNA, TH, MA, SA, JB, MB, CB, PB, XC, UD,
GD, AMD, TE, MF, SFF, KF, JMG, DG, OG, BCH, TH, BH, MAH, ELH,
CH, FMH, KNJ, TK, RK, RKL, TVL, CM, GM, IM, EMTM, PBM, LN, VO,
LO, NO, MCO, BJO, EP, RR, CMB, JR, MMR, GR, HGR, SS, JS, AHS,
KS, MGS, MS, FS, HST, DJV, LW, OAA, IA, UFM, EB, AMM. Manu-
script revision: UKH, MB, TPG, TE, MA, DA, SA, JB, FB, EJC, XC, UD,
MF, KF, JMF, DG, OG, OD, BCMH, BCH, BTB, TH, MAH, CH, FMH,
KNJ, BK, TVL, TML, RKL, IM, PBM, NO, EP, JR, GR, RS, HGR, SS, JS,
KS, MGS, DJS, CKT, HST, DvdM, TGMvE, EV, LW, LTW, NJ, LES,
PMT, CRKC, OAA, AMM, EB.
DATA AVAILABILITY STATEMENT
The datasets from this study will not be made publicly available as we
do not have approvals for sharing clinical data.
ORCID
Unn K. Haukvik https://orcid.org/0000-0002-0363-4127
Tiril P. Gurholt https://orcid.org/0000-0002-1272-7616
Bernd Krämer https://orcid.org/0000-0002-1145-9103
Thomas M. Lancaster https://orcid.org/0000-0003-1322-2449
Igor Nenadic https://orcid.org/0000-0002-0749-7473
Joaquim Radua https://orcid.org/0000-0003-1240-5438
Ronny Redlich https://orcid.org/0000-0002-7018-4525
Jonathan Repple https://orcid.org/0000-0003-1379-9491
Raymond Salvador https://orcid.org/0000-0001-5557-1562
Sophia I. Thomopoulos https://orcid.org/0000-0002-0046-4070
Lars T. Westlye https://orcid.org/0000-0001-8644-956X
Philipp G. Sämann https://orcid.org/0000-0001-8523-3628
REFERENCES
Aas, M., Haukvik, U. K., Djurovic, S., Tesli, M., Athanasiu, L., Bjella, T., …
Melle, I. (2014). Interplay between childhood trauma and BDNF
val66met variants on blood BDNF mRNA levels and on hippocampus
subfields volumes in schizophrenia spectrum and bipolar disorders.
Journal of Psychiatric Research, 59, 14–21. https://doi.org/10.1016/j.
jpsychires.2014.08.011
Amaral, D. G., Scharfman, H. E., & Lavenex, P. (2007). The dentate gyrus:
Fundamental neuroanatomical organization (dentate gyrus for
dummies). Progress in Brain Research, 163, 3–22. https://doi.org/10.
1016/s0079-6123(07)63001-5
Balu, D. T., & Lucki, I. (2009). Adult hippocampal neurogenesis: Regulation,
functional implications, and contribution to disease pathology. Neuro-
science and Biobehavioral Reviews, 33(3), 232–252. https://doi.org/10.
1016/j.neubiorev.2008.08.007
Bearden, C. E., Thompson, P. M., Dutton, R. A., Frey, B. N., Peluso, M. A.,
Nicoletti, M., … Soares, J. C. (2008). Three-dimensional mapping of
hippocampal anatomy in unmedicated and lithium-treated patients
with bipolar disorder. Neuropsychopharmacology, 33(6), 1229–1238.
https://doi.org/10.1038/sj.npp.1301507
Berk, M., Dandash, O., Daglas, R., Cotton, S. M., Allott, K., Fornito, A., …
Yucel, M. (2017). Neuroprotection after a first episode of mania: A
randomized controlled maintenance trial comparing the effects of lith-
ium and quetiapine on grey and white matter volume. Translational
Psychiatry, 7(1), e1011. https://doi.org/10.1038/tp.2016.281
Bodnar, M., Malla, A. K., Makowski, C., Chakravarty, M. M., Joober, R., &
Lepage, M. (2016). The effect of second-generation antipsychotics on
hippocampal volume in first episode of psychosis: Longitudinal study.
BJPsych Open, 2(2), 139–146. https://doi.org/10.1192/bjpo.bp.115.
002444
Boedhoe, P. S. W., Heymans, M. W., Schmaal, L., Abe, Y., Alonso, P.,
Ameis, S. H., … Twisk, J. W. R. (2018). An empirical comparison of
meta- and mega-analysis with data from the ENIGMA obsessive-
compulsive disorder working group. Frontiers in Neuroinformatics, 12,
102. https://doi.org/10.3389/fninf.2018.00102
Boldrini, M., Hen, R., Underwood, M. D., Rosoklija, G. B., Dwork, A. J.,
Mann, J. J., & Arango, V. (2012). Hippocampal angiogenesis and
12 HAUKVIK ET AL.
progenitor cell proliferation are increased with antidepressant use in
major depression. Biological Psychiatry, 72(7), 562–571. https://doi.
org/10.1016/j.biopsych.2012.04.024
Brown, E. M., Pierce, M. E., Clark, D. C., Fischl, B. R., Iglesias, J. E.,
Milberg, W. P., … Salat, D. H. (2020). Test-retest reliability of
FreeSurfer automated hippocampal subfield segmentation within and
across scanners. NeuroImage, 210, 116563. https://doi.org/10.1016/j.
neuroimage.2020.116563
Cao, B., Passos, I. C., Mwangi, B., Amaral-Silva, H., Tannous, J., Wu, M. J.,
… Soares, J. C. (2017). Hippocampal subfield volumes in mood disor-
ders. Molecular Psychiatry, 22(9), 1352–1358. https://doi.org/10.
1038/mp.2016.262
Crum, W. R., Danckaers, F., Huysmans, T., Cotel, M. C., Natesan, S.,
Modo, M. M., … Vernon, A. C. (2016). Chronic exposure to haloperidol
and olanzapine leads to common and divergent shape changes in the
rat hippocampus in the absence of grey-matter volume loss. Psycholog-
ical Medicine, 46(15), 3081–3093. https://doi.org/10.1017/
s0033291716001768
Dalton, M. A., & Maguire, E. A. (2017). The pre/parasubiculum: A hippo-
campal hub for scene-based cognition? Current Opinion in Behavioral
Sciences, 17, 34–40. https://doi.org/10.1016/j.cobeha.2017.06.001
Fanselow, M. S., & Dong, H. W. (2010). Are the dorsal and ventral hippo-
campus functionally distinct structures? Neuron, 65(1), 7–19. https://
doi.org/10.1016/j.neuron.2009.11.031
Ferensztajn-Rochowiak, E., & Rybakowski, J. K. (2016). The effect of lith-
ium on hematopoietic, mesenchymal and neural stem cells. Pharmaco-
logical Reports, 68(2), 224–230. https://doi.org/10.1016/j.pharep.
2015.09.005
Fjell, A. M., Westlye, L. T., Grydeland, H., Amlien, I., Espeseth, T.,
Reinvang, I., … Walhovd, K. B. (2013). Critical ages in the life course of
the adult brain: Nonlinear subcortical aging. Neurobiology of Aging, 34
(10), 2239–2247. https://doi.org/10.1016/j.neurobiolaging.2013.
04.006
Fusar-Poli, P., Smieskova, R., Kempton, M. J., Ho, B. C.,
Andreasen, N. C., & Borgwardt, S. (2013). Progressive brain changes in
schizophrenia related to antipsychotic treatment? A meta-analysis of
longitudinal MRI studies. Neuroscience and Biobehavioral Reviews, 37
(8), 1680–1691. https://doi.org/10.1016/j.neubiorev.2013.06.001
Grande, I., Berk, M., Birmaher, B., & Vieta, E. (2016). Bipolar disorder. Lan-
cet, 387(10027), 1561–1572. https://doi.org/10.1016/s0140-6736
(15)00241-x
Harrison, P. J., Colbourne, L., & Harrison, C. H. (2020). The neuropathology
of bipolar disorder: Systematic review and meta-analysis. Molecular
Psychiatry, 25, 1787–1808. https://doi.org/10.1038/s41380-41018-
40213-41383
Hartberg, C. B., Jorgensen, K. N., Haukvik, U. K., Westlye, L. T., Melle, I.,
Andreassen, O. A., & Agartz, I. (2015). Lithium treatment and hippo-
campal subfields and amygdala volumes in bipolar disorder. Bipolar Dis-
orders, 17(5), 496–506. https://doi.org/10.1111/bdi.12295
Haukvik, U. K., Tamnes, C. K., Soderman, E., & Agartz, I. (2018). Neuroim-
aging hippocampal subfields in schizophrenia and bipolar disorder: A
systematic review and meta-analysis. Journal of Psychiatric Research,
104, 217–226. https://doi.org/10.1016/j.jpsychires.2018.08.012
Haukvik, U. K., Westlye, L. T., Morch-Johnsen, L., Jorgensen, K. N.,
Lange, E. H., Dale, A. M., … Agartz, I. (2015). In vivo hippocampal sub-
field volumes in schizophrenia and bipolar disorder. Biological Psychia-
try, 77(6), 581–588. https://doi.org/10.1016/j.biopsych.2014.06.020
Hibar, D. P., Westlye, L. T., van Erp, T. G., Rasmussen, J., Leonardo, C. D.,
Faskowitz, J., … Andreassen, O. A. (2016). Subcortical volumetric
abnormalities in bipolar disorder. Molecular Psychiatry, 21(12),
1710–1716. https://doi.org/10.1038/mp.2015.227
Iglesias, J. E., Augustinack, J. C., Nguyen, K., Player, C. M., Player, A.,
Wright, M., … Alzheimer's Disease Neuroimaging Initiative. (2015). A
computational atlas of the hippocampal formation using ex vivo, ultra-
high resolution MRI: Application to adaptive segmentation of in vivo
MRI. NeuroImage, 115, 117–137. https://doi.org/10.1016/j.
neuroimage.2015.04.042
Katsuki, A., Watanabe, K., Nguyen, L., Otsuka, Y., Igata, R., Ikenouchi, A., …
Yoshimura, R. (2020). Structural changes in Hippocampal Subfields in
patients with continuous remission of drug-naive major depressive dis-
order. International Journal of Molecular Sciences, 21(9). https://doi.
org/10.3390/ijms21093032
Konradi, C., Zimmerman, E. I., Yang, C. K., Lohmann, K. M., Gresch, P.,
Pantazopoulos, H., … Heckers, S. (2011). Hippocampal interneurons in
bipolar disorder. Archives of General Psychiatry, 68(4), 340–350.
https://doi.org/10.1001/archgenpsychiatry.2010.175
Malchow, B., Strocka, S., Frank, F., Bernstein, H. G., Steiner, J., Schneider-
Axmann, T., … Schmitt, A. (2015). Stereological investigation of the
posterior hippocampus in affective disorders. Journal of Neural Trans-
mission (Vienna), 122(7), 1019–1033. https://doi.org/10.1007/
s00702-014-1316-x
Maller, J. J., Broadhouse, K., Rush, A. J., Gordon, E., Koslow, S., &
Grieve, S. M. (2018). Increased hippocampal tail volume predicts
depression status and remission to anti-depressant medications in
major depression. Molecular Psychiatry, 23(8), 1737–1744. https://doi.
org/10.1038/mp.2017.224
Mathew, I., Gardin, T. M., Tandon, N., Eack, S., Francis, A. N.,
Seidman, L. J., … Keshavan, M. S. (2014). Medial temporal lobe struc-
tures and hippocampal subfields in psychotic disorders: Findings from
the bipolar-schizophrenia network on intermediate phenotypes (B-
SNIP) study. JAMA Psychiatry, 71(7), 769–777. https://doi.org/10.
1001/jamapsychiatry.2014.453
Mertens, J., Wang, Q. W., Kim, Y., Yu, D. X., Pham, S., Yang, B., … Yao, J.
(2015). Differential responses to lithium in hyperexcitable neurons
from patients with bipolar disorder. Nature, 527(7576), 95–99.
https://doi.org/10.1038/nature15526
Mueller, S. G., Yushkevich, P. A., Das, S., Wang, L., Van Leemput, K.,
Iglesias, J. E., … Weiner, M. W. (2018). Systematic comparison of dif-
ferent techniques to measure hippocampal subfield volumes in ADNI2.
Neuroimage: Clinical, 17, 1006–1018. https://doi.org/10.1016/j.nicl.
2017.12.036
Nakagawa, S., & Cuthill, I. C. (2007). Effect size, confidence interval and
statistical significance: A practical guide for biologists. Biological
Reviews of the Cambridge Philosophical Society, 82(4), 591–605.
https://doi.org/10.1111/j.1469-185X.2007.00027.x
Open Science Collaboration. (2015). PSYCHOLOGY. Estimating the repro-
ducibility of psychological science. Science, 349(6251), aac4716.
https://doi.org/10.1126/science.aac4716
Paulus, M. P., & Thompson, W. K. (2019). The challenges and opportunities
of small effects: The new Normal in academic psychiatry. JAMA Psychi-
atry, 76(4), 353–354. https://doi.org/10.1001/jamapsychiatry.2018.
4540
Phillips, M. L., & Kupfer, D. J. (2013). Bipolar disorder diagnosis: Challenges
and future directions. Lancet, 381(9878), 1663–1671. https://doi.org/
10.1016/s0140-6736(13)60989-7
Pipitone, J., Park, M. T., Winterburn, J., Lett, T. A., Lerch, J. P.,
Pruessner, J. C., … Alzheimer's Disease Neuroimaging Initiative. (2014).
Multi-atlas segmentation of the whole hippocampus and subfields
using multiple automatically generated templates. NeuroImage, 101,
494–512. https://doi.org/10.1016/j.neuroimage.2014.04.054
Rajkowska, G., Clarke, G., Mahajan, G., Licht, C. M., Van De Werd, H. J.,
Yuan, P., … Uylings, H. B. (2016). Differential effect of lithium on cell
number in the hippocampus and prefrontal cortex in adult mice: A ste-
reological study. Bipolar Disorders, 18(1), 41–51. https://doi.org/10.
1111/bdi.12364
Schmaal, L., Veltman, D. J., van Erp, T. G., Samann, P. G., Frodl, T.,
Jahanshad, N., … Hibar, D. P. (2016). Subcortical brain alterations in
major depressive disorder: Findings from the ENIGMA major depres-
sive disorder working group. Molecular Psychiatry, 21(6), 806–812.
https://doi.org/10.1038/mp.2015.69
HAUKVIK ET AL. 13
Schmitt, A., Weber, S., Jatzko, A., Braus, D. F., & Henn, F. A. (2004). Hippo-
campal volume and cell proliferation after acute and chronic clozapine
or haloperidol treatment. Journal of Neural Transmission (Vienna), 111
(1), 91–100. https://doi.org/10.1007/s00702-003-0070-2
Simonetti, A., Sani, G., Dacquino, C., Piras, F., De Rossi, P., Caltagirone, C.,
… Spalletta, G. (2016). Hippocampal subfield volumes in short- and
long-term lithium-treated patients with bipolar I disorder. Bipolar Dis-
orders, 18(4), 352–362. https://doi.org/10.1111/bdi.12394
Simonnet, J., Nassar, M., Stella, F., Cohen, I., Mathon, B., Boccara, C. N., …
Fricker, D. (2017). Activity dependent feedback inhibition may main-
tain head direction signals in mouse presubiculum. Nature Communica-
tions, 8, 16032. https://doi.org/10.1038/ncomms16032
Squire, L. R., & Wixted, J. T. (2011). The cognitive neuroscience of human
memory since H.M. Annual Review of Neuroscience, 34, 259–288.
https://doi.org/10.1146/annurev-neuro-061010-113720
Stern, S., Santos, R., Marchetto, M. C., Mendes, A. P. D., Rouleau, G. A.,
Biesmans, S., … Gage, F. H. (2018). Neurons derived from patients with
bipolar disorder divide into intrinsically different sub-populations of
neurons, predicting the patients' responsiveness to lithium. Molecular
Psychiatry, 23(6), 1453–1465. https://doi.org/10.1038/mp.2016.260
Tamminga, C. A., Stan, A. D., & Wagner, A. D. (2010). The hippocampal for-
mation in schizophrenia. The American Journal of Psychiatry, 167(10),
1178–1193. https://doi.org/10.1176/appi.ajp.2010.09081187
Teicher, M. H., Anderson, C. M., & Polcari, A. (2012). Childhood maltreat-
ment is associated with reduced volume in the hippocampal subfields
CA3, dentate gyrus, and subiculum. Proceedings of the National Acad-
emy of Sciences of the United States of America, 109(9), E563–E572.
https://doi.org/10.1073/pnas.1115396109
Thompson, P. M., Ching, C. R. K., Dennis, E. L., Salminen, L. E.,
Turner, J. A., Van Erp, T. G. M., & Jahanshad, N. (2020). Big data initia-
tives in psychiatry: Global Neuroimaging studies. In M. Kubicki & M. E.
Shenton (Eds.), Neuroimaging in Schizophrenia (pp. 411–426). Cham:
Springer International Publishing.
van Erp, T. G., Hibar, D. P., Rasmussen, J. M., Glahn, D. C., Pearlson, G. D.,
Andreassen, O. A., … Turner, J. A. (2016). Subcortical brain volume
abnormalities in 2028 individuals with schizophrenia and 2540 healthy
controls via the ENIGMA consortium. Molecular Psychiatry, 21(4),
547–553. https://doi.org/10.1038/mp.2015.63
Van Leemput, K., Bakkour, A., Benner, T., Wiggins, G., Wald, L. L.,
Augustinack, J., … Fischl, B. (2009). Automated segmentation of hippo-
campal subfields from ultra-high resolution in vivo MRI. Hippocampus,
19(6), 549–557. https://doi.org/10.1002/hipo.20615
Wang, A. Y., Lohmann, K. M., Yang, C. K., Zimmerman, E. I.,
Pantazopoulos, H., Herring, N., … Konradi, C. (2011). Bipolar disorder
type 1 and schizophrenia are accompanied by decreased density of
parvalbumin- and somatostatin-positive interneurons in the para-
hippocampal region. Acta Neuropathologica, 122(5), 615–626. https://
doi.org/10.1007/s00401-011-0881-4
Westlye, L. T., Alnaes, D., van der Meer, D., Kaufmann, T., &
Andreassen, O. A. (2019). Population-based mapping of polygenic risk
for schizophrenia on the human brain: New opportunities to capture
the dimensional aspects of severe mental disorders. Biological
Psychiatry, 86(7), 499–501. https://doi.org/10.1016/j.biopsych.2019.
08.001
Yushkevich, P. A., Amaral, R. S., Augustinack, J. C., Bender, A. R.,
Bernstein, J. D., Boccardi, M., … Hippocampal Subfields, G. (2015).
Quantitative comparison of 21 protocols for labeling hippocampal sub-
fields and parahippocampal subregions in in vivo MRI: Towards a har-
monized segmentation protocol. NeuroImage, 111, 526–541. https://
doi.org/10.1016/j.neuroimage.2015.01.004
Yushkevich, P. A., Wang, H., Pluta, J., Das, S. R., Craige, C., Avants, B. B., …
Mueller, S. (2010). Nearly automatic segmentation of hippocampal
subfields in in vivo focal T2-weighted MRI. NeuroImage, 53(4),
1208–1224. https://doi.org/10.1016/j.neuroimage.2010.06.040
Zanni, G., Michno, W., Di Martino, E., Tjarnlund-Wolf, A., Pettersson, J.,
Mason, C. E., … Hanrieder, J. (2017). Lithium accumulates in neuro-
genic brain regions as revealed by high resolution ion imaging. Scien-
tific Reports, 7, 40726. https://doi.org/10.1038/srep40726
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article: Haukvik UK, Gurholt TP, Nerland S,
et al. In vivo hippocampal subfield volumes in bipolar
disorder—A mega-analysis from The Enhancing Neuro Imaging
Genetics through Meta-Analysis Bipolar Disorder Working
Group. Hum Brain Mapp. 2020;1–14. https://doi.org/10.1002/
hbm.25249
14 HAUKVIK ET AL.
